HGEN - Humanigen secures $92.5M via equity raise

Humanigen (HGEN) has priced its public offering of 5M common shares at 18.50/share, resulting in gross proceeds of ~$92.5M.Underwriters' over-allotment is an additional 750K shares. Net proceeds will be used for manufacturing and commercial preparation of COVID-19 candidate lenzilumab in the event of FDA Emergency Use Authorization, for working capital and other general corporate purposes.Jefferies, Credit Suisse and Cantor are acting as joint book-running managers.Closing date is April 5.Shares down 2.5% after-hours.Previously (March 29): Humanigen begins underwritten offering of 5M shares

For further details see:

Humanigen secures $92.5M via equity raise